Ionis Price To Sales Ratio from 2010 to 2024

IONS Stock  USD 38.95  0.92  2.31%   
Ionis Pharmaceuticals Price To Sales Ratio yearly trend continues to be comparatively stable with very little volatility. Price To Sales Ratio is likely to outpace its year average in 2024. Price To Sales Ratio is a valuation ratio that compares a company’s stock price to its revenues, calculated by dividing the company’s market cap by its total sales or revenue over a 12-month period. View All Fundamentals
 
Price To Sales Ratio  
First Reported
2010-12-31
Previous Quarter
9.19699066
Current Value
15.6
Quarterly Volatility
9.71809226
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Ionis Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ionis Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 23.6 M, Interest Expense of 79.4 M or Total Revenue of 827 M, as well as many indicators such as Price To Sales Ratio of 15.6, Dividend Yield of 0.0 or PTB Ratio of 17.8. Ionis financial statements analysis is a perfect complement when working with Ionis Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Ionis Pharmaceuticals Correlation against competitors.
For more information on how to buy Ionis Stock please use our How to Invest in Ionis Pharmaceuticals guide.

Latest Ionis Pharmaceuticals' Price To Sales Ratio Growth Pattern

Below is the plot of the Price To Sales Ratio of Ionis Pharmaceuticals over the last few years. Price to Sales Ratio is figured by comparing Ionis Pharmaceuticals stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Ionis Pharmaceuticals sales, a figure that is much harder to manipulate than other Ionis Pharmaceuticals multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. It is a valuation ratio that compares a company’s stock price to its revenues, calculated by dividing the company’s market cap by its total sales or revenue over a 12-month period. Ionis Pharmaceuticals' Price To Sales Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ionis Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 7.72 X10 Years Trend
Slightly volatile
   Price To Sales Ratio   
       Timeline  

Ionis Price To Sales Ratio Regression Statistics

Arithmetic Mean15.87
Geometric Mean13.47
Coefficient Of Variation61.25
Mean Deviation7.91
Median11.93
Standard Deviation9.72
Sample Variance94.44
Range28.631
R-Value(0.52)
Mean Square Error73.68
R-Squared0.28
Significance0.04
Slope(1.14)
Total Sum of Squares1,322

Ionis Price To Sales Ratio History

2024 15.6
2023 9.2
2022 9.13
2021 5.3
2020 10.83
2019 7.53
2018 11.93

About Ionis Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Ionis Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Ionis Pharmaceuticals investors use historical funamental indicators, such as Ionis Pharmaceuticals's Price To Sales Ratio, to determine how well the company is positioned to perform in the future. Although Ionis Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Ionis Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Ionis Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Ionis Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Ionis Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Price To Sales Ratio 9.20  15.60 

Pair Trading with Ionis Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Ionis Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ionis Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Ionis Stock

  0.69ELEV Elevation OncologyPairCorr
  0.72ENVB Enveric BiosciencesPairCorr
  0.69EVOK Evoke PharmaPairCorr
  0.82EXEL ExelixisPairCorr

Moving against Ionis Stock

  0.7UPC Universe PharmaceuticalsPairCorr
  0.6HALO Halozyme TherapeuticsPairCorr
  0.55PFE Pfizer Inc Financial Report 6th of August 2024 PairCorr
  0.5LLY Eli LillyPairCorr
  0.49QLI Qilian InternationalPairCorr
The ability to find closely correlated positions to Ionis Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Ionis Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Ionis Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Ionis Pharmaceuticals to buy it.
The correlation of Ionis Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Ionis Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Ionis Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Ionis Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Ionis Stock Analysis

When running Ionis Pharmaceuticals' price analysis, check to measure Ionis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ionis Pharmaceuticals is operating at the current time. Most of Ionis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ionis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ionis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ionis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.